Stocktoria
Vir Biotechnology, Inc. VIR
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2019-10-11
Chart by TradingView
2/9
Piotroski F — financial health
-0.97
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Financials | |||||
| Revenue | $68.6M | $74.2M | $86.2M | $1.6B | $1.1B |
| Operating income | -$479.3M | -$587.2M | -$684.3M | $833.1M | $420.8M |
| Net income | -$438.0M | -$522.0M | -$615.1M | $515.8M | $528.6M |
| Operating cash flow | -$391.8M | -$446.4M | -$778.8M | $1.7B | -$47.6M |
| Free cash flow | -$396.6M | -$453.7M | -$800.4M | $1.6B | -$69.4M |
| Total assets | $1.0B | $1.4B | $1.9B | $2.8B | $2.0B |
| Total liabilities | $237.5M | $248.4M | $328.8M | $724.1M | $522.4M |
| Shareholders' equity | $765.3M | $1.2B | $1.6B | $2.1B | $1.4B |
| Ratios | |||||
| Operating margin | -699.2% | -791.3% | -794.0% | 51.6% | 38.4% |
| Net margin | -638.9% | -703.4% | -713.7% | 31.9% | 48.3% |
| FCF margin | -578.5% | -611.4% | -928.7% | 98.7% | -6.3% |
| Return on assets | -43.7% | -37.3% | -32.1% | 18.4% | 27.0% |
| Return on equity | -57.2% | -45.4% | -38.7% | 24.8% | 36.9% |
| Current ratio | 5.54 | 8.71 | 9.05 | 4.93 | 4.58 |
| Revenue growth | -7.6% | -13.9% | -94.7% | 47.5% | 1334.4% |
Notable holders (13F)
| Investor | Shares | Value |
|---|---|---|
| Point72 Asset Management, L.P. | 1,952,234 | $17.5M |
| RENAISSANCE TECHNOLOGIES LLC | 761,364 | $6.8M |
Why these scores methodology →
Piotroski F-score: 2/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -0.97 (distress)
- Working capital / assets 0.42
- Retained earnings / assets -1.194
- EBIT / assets -0.478
- Equity / liabilities 3.222
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001706431 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.